Investing

Viridian Therapeutics : VRDN

VRDN

Stock Data

$16.35

$0.21 (1.30%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Viridian Therapeutics, Inc., based in Waltham, Massachusetts, is a biotechnology firm focused on developing treatments for serious and rare diseases. Its leading projects include VRDN-001, a monoclonal antibody for thyroid eye disease, now in Phase 3 trials, and VRDN-003, a next-generation antibody with potential for the same condition. The company also explores treatments for autoimmune diseases through its preclinical programs VRDN-006 and VRDN-008. Founded in 2010 and originally known as Miragen Therapeutics, it rebranded to Viridian Therapeutics in 2021.

All Viridian Therapeutics Articles

4 Articles

Trey Thoelcke | Dec 12, 2025 at 8:45 AM EST

Huge Insider Buying in MGM and Salesforce

As the year winds down, insiders make huge buys in MGM Resorts and Salesforce. However, those were not the only…

Omor Ibne Ehsan | Oct 28, 2025 at 2:21 PM EDT

Insiders Are Buying These 3 Stocks Hand Over Fist

Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management…

Trey Thoelcke | Sep 22, 2024 at 9:15 AM EDT

Last Week’s 3 Biotech IPOs Prompt Huge Insider Buying

IPOs at three biotechs last week tempted insiders to make huge purchases of shares. This effect spilled over into buying…

Trey Thoelcke | Jan 27, 2024 at 1:09 PM EST

Huge Insider Buys From Warren Buffett, Jack Ma, Carlos Slim and More

Recent insider buying has been highlighted by purchases by Warren Buffett, Jack Ma, Carlos Slim, and John Paulson. Biotechs tempted…